Variants of genes implicated in type 1 interferon pathway and B-cell activation modulate the EULAR response to rituximab at 24 weeks in rheumatoid arthritis

BACKGROUND: The type 1 interferon (IFN) pathway has been identified to potentially affect the response to rituximab (RTX) for rheumatoid arthritis (RA), which suggests the contribution of type 1 IFN pathway genes such as IFN regulatory factor 5 and 7 (IRF5 and IRF7), tyrosine kinase 2 (TYK2), signal...

Descripción completa

Detalles Bibliográficos
Autores principales: Juge, Pierre-Antoine, Gazal, Steven, Constantin, Arnaud, Mariette, Xavier, Combe, Bernard, Tebib, Jacques, Dougados, Maxime, Sibilia, Jean, Le Loet, Xavier, Dieudé, Philippe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2017
Materias:
Rheumatoid Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5640092/
https://www.ncbi.nlm.nih.gov/pubmed/29071117
http://dx.doi.org/10.1136/rmdopen-2017-000448

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5640092/
https://www.ncbi.nlm.nih.gov/pubmed/29071117
http://dx.doi.org/10.1136/rmdopen-2017-000448

Ejemplares similares